Article Text

THU0203 Changes in c-reactive protein and lipid levels in patients with rheumatoid arthritis treated with abt-494, a selective jak-1 inhibitor
  1. M Nurmohamed1,
  2. Y Zhang2,
  3. J Lin2,
  4. H Camp2
  1. 1Amsterdam Rheumatology Immunology Ctr, VU Univ Medical Ctr, Amsterdam, Netherlands
  2. 2AbbVie, N Chicago, United States


Background In patients (pts) with rheumatoid arthritis (RA) treated with ABT-494, dose-dependent increases in levels of low and high density lipoprotein cholesterol (LDL-C and HDL-C) were observed, along with decreases in levels of C-reactive Protein (CRP). Whether these changes are due to the control of inflammation or a direct effect on CRP production in the liver is not known.

Objectives To explore the relationship between changes in HDL-C or LDL-C and CRP with ABT-494 treatment, and to assess whether the effect on lipids is dependent on improvement of RA signs and symptoms.

Methods Data were from two phase 2b controlled trials of ABT-494 in RA pts with inadequate response or intolerance to TNF inhibitors (TNF-IR, BALANCE-1)1, or with inadequate response to methotrexate (MTX-IR, BALANCE-2)2. Pts treated with placebo or 3,6,12,18 mg ABT-494 twice daily for 12 weeks (wks) are included. Levels of high sensitivity (hs) CRP, total cholesterol (TC), LDL-C and HDL-C were measured at baseline (BL) and Wk 2,4,6, 8 and 12. Atherogenic burden at BL and Wk 12 was assessed by ratio of ApoB:ApoA1 and TC:HDL-C in 6 mg and 12 mg dose groups in both studies. Pearson's coefficients were calculated post hoc to assess possible correlations between HDL-C or LDL-C levels (or changes from BL) with other variables including (high sensitivity) hsCRP, at BL and Wk 12. Pts were subgrouped by response: Sustained responders (SR), pts who achieved an ACR20 response at every visit from Wk 2–12; Responders (R), pts who achieved ACR20 at least once, but not at every visit; Non-responders (NR), pts who did not achieve ACR20 at any visit.

Results The ratios of LDL-C:HDL-C1,2 and TC:HDL-C remained unchanged after 12 wks of treatment with ABT-494. The ratio of ApoB:ApoA1 also remained unchanged from BL to Wk 12: in BALANCE-1, 0.61 to 0.58 for the 6 mg (n=19), and 0.62 to 0.60 for 12 mg (n=11) groups, and in BALANCE-2, 0.62 to 0.64 for the 6 mg (n=18) and 0.69 to 0.66 for 12 mg (n=16) groups. An inverse relationship between LDL-C or HDL-C and hsCRP was observed throughout the treatment period. At Wk 4, among the variables tested, the strongest correlation was observed between changes from BL in hsCRP and LDL-C (-0.29, p<0.001) or HDL-C (-0.26, p<0.001). Out of 420 pts, 104 pts (25%) were ACR20 SR, 251 pts (60%) were R and 65 pts (15%) were NR. Compared to NR, SR and R had a greater absolute reduction in hsCRP (Fig. 1A). A robust percentage increase in HDL-C was observed in all 3 groups (20.8%, 18.5% and 16.4% in SR, R and NR, respectively). Compared to the SR and R (14.6% and 16%, respectively), a smaller percentage increase in LDL-C was observed in the NR (8.9%) (Fig. 1B).

Conclusions Atherogenic burden did not increase in pts treated with ABT-494 for 12 wks. Compared to non-responders, pts with a clinical response experienced a larger increase in lipids and a larger decrease in hsCRP. Limited data from these phase 2 studies suggest that there might not be an increased risk of cardiovascular events. Results from the larger phase 3 trials can provide more information.


  1. Kremer et al. 2016, Arthritis & Rheum;68:2867.

  2. Genovese et al. 2016, Arthritis & Rheum;68:2857.


Acknowledgements AbbVie: study sponsor, contributed to study design, data collection, analysis and interpretation; writing, reviewing, and approval of the final version. Medical writing: Naina Barretto, of AbbVie.

Disclosure of Interest M. Nurmohamed Grant/research support from: Abbvie, Bristol–Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Janssen, UCB and Sanofi., Consultant for: Abbvie, Bristol–Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Janssen, UCB and Sanofi., Y. Zhang Employee of: AbbVie, J. Lin Employee of: AbbVie, H. Camp Employee of: AbbVie

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.